More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

Wales is past the peak of its flu season according to public health bosses. Cases of flu have caused chaos in Wales' ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...